subscribeSubscribe
Takeda Announces Phase 3 Trial of ALUNBRIG® (brigatinib) Met Primary Endpoint

Takeda Announces Phase 3 Trial of ALUNBRIG® (brigatinib) Met Primary Endpoint
TAKEDAONCOLOGY
22 Jan 2021
Share Share
Alunbrig scores NICE backing for ALK-positive lung cancer

Alunbrig scores NICE backing for ALK-positive lung cancer
Lucy Parsons PHARMATIMES
11 Dec 2020
Share Share
NICE authorises Takeda`s Alunbrig for ALK-positive advanced NSCLC

NICE authorises Takeda`s Alunbrig for ALK-positive advanced NSCLC
PHARMAFILE
10 Dec 2020
Share Share
ALUNBRIG?(brigatinib) now available on the NHS in England

ALUNBRIG?(brigatinib) now available on the NHS in England
PHARMIWEB
10 Dec 2020
Share Share
Takeda Presents New Data On Scientific Advances In Lung Cancer At ESMO

Takeda Presents New Data On Scientific Advances In Lung Cancer At ESMO
BUSINESSWIRE
21 Sep 2020
Share Share
New US approval for Takeda’s Alunbrig

New US approval for Takeda’s Alunbrig
Selina McKee PHARMA TIMES
25 May 2020
Share Share
U.S. FDA Approves Takeda’s ALUNBRIG® (brigatinib) as a First-Line Treatment

U.S. FDA Approves Takeda’s ALUNBRIG® (brigatinib) as a First-Line Treatment
BUSINESSWIRE
22 May 2020
Share Share
U.S. FDA Approves Takeda’s ALUNBRIG® (brigatinib) as a First-Line Treatment

U.S. FDA Approves Takeda’s ALUNBRIG® (brigatinib) as a First-Line Treatment
BUSINESSWIRE
22 May 2020
Share Share
Expanded EU approval for Takeda`s Alunbrig

Expanded EU approval for Takeda`s Alunbrig
Selina McKee PHARMATIMES
08 Apr 2020
Share Share
Takeda’s Alunbrig receives European marketing approval for ALK+ NSCLC

Takeda’s Alunbrig receives European marketing approval for ALK+ NSCLC
PHARMABIZ
07 Apr 2020
Share Share